ReviewBritish journal of haematology2025
Anaplastic large cell lymphoma in children and adolescents.
Review in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A Phase 1 Study to Assess the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate-Release Tablet in Healthy Adults.Clinical pharmacology in drug development · 2026Trial
- Article
- Article
- Anaplastic large-cell lymphoma mimicking cellulitis in an 8-year-old boy.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- ALK-negative anaplastic large cell lymphoma in pediatric and adolescent patients: a mini-review.Frontiers in oncology · 2026Review
- Anaplastic large cell lymphoma in children and adolescents.British journal of haematology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALCL) accounts for >95% of ALCL cases in children and adolescents. The first description of ALCL as a CD30-positive lymphoma in 1985 was followed by the detection of chromosomal translocations involving the ALK gene at chromosome 2p23. The pathogenesis of ALK-positive ALCL is based on signalling from the constitutive active ALK kinase. The clinical characteristics, therapy regimens and outcome data were reported in the 1990s and 2000s. Different chemotherapy regimens led to astonishingly similar long-term event-free survival rates of 70%, independent of the drugs, doses and duration of therapy. Additionally, patients with relapsed ALCL are treated successfully with very different re-induction and consolidation approaches leading to an overall survival approaching 95%. In the 2010s, minimal disseminated and residual disease, histological subtype and antibody titres against ALK were reported as significant independent prognostic factors. Over the last 15 years, targeted therapies (brentuximab vedotin, ALK inhibitors) have demonstrated high efficacy with low toxicity. The future of ALK-positive ALCL is to define the role of targeted therapies by developing a 'chemotherapy-free' approach for patients with standard-risk ALCL and an integrated approach to cure patients with high-risk ALCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.